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Cognitive deficits in various domains have been shown in patients with bipolar disorder and schizophrenia. The purpose of the
present study was to examine if residual psychopathology explained the difference in cognitive function between clinically stable
patients with schizophrenia and bipolar disorder. We compared the performance on tests of attention, visual and verbal memory,
and executive function of 25 patients with schizophrenia in remission and 25 euthymic bipolar disorder patients with that of
25 healthy controls. Mediation analysis was used to see if residual psychopathology could explain the difference in cognitive
function between the patient groups. Both patient groups performed significantly worse than healthy controls on most cognitive
tests. Patients with bipolar disorder displayed cognitive deficits that were milder but qualitatively similar to those of patients with
schizophrenia. Residual negative symptoms mediated the difference in performance on cognitive tests between the two groups.
Neither residual general psychotic symptoms nor greater antipsychotic doses explained this relationship. The shared variance
explained by the residual negative and cognitive deficits that the difference between patient groups may be explained by greater
frontal cortical neurophysiological deficits in patients with schizophrenia, compared to bipolar disorder. Further longitudinal work
may provide insight into pathophysiological mechanisms that underlie these deficits.
1. Introduction
Cognitive deficits represent stable traits in both schizophre-
nia and bipolar disorder [1]. Studies that have directly
compared the two groups show qualitatively similar deficits,
but quantitatively, milder deficits in bipolar disorder [2–
4]. More recently, it has been postulated that this quanti-
tative difference may depend on the presence or severity
of psychotic symptoms [5, 6]. For example, Simonsen et al.
found that as compared to those without psychosis, subjects
with a history of psychosis, irrespective of the diagnosis,
showed poorer performance on neurocognitivemeasures [5].
Additionally, depressive and negative symptoms have also
been associated with cognitive deficits [7, 8]. However, very
few studies have tried to address these issues during symp-
tomatic remission. It is not clear if residual/subthreshold
psychopathology during periods of remission would explain
the trait difference between the two groups. In other words,
do patients with schizophrenia perform poorer on cognitive
tests than patients with bipolar disorder, due to the presence
of residual/subthreshold psychotic/negative symptoms?
In this study, we aimed to compare cognitive function
in patients with euthymic bipolar disorder with those with
schizophrenia in remission. Our second aim was to examine
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if differences in residual symptoms (psychotic/negative
symptoms) between the patient groups could explain (medi-
ate) the difference in cognitive dysfunction between the
groups. In other words, the question we are attempting
to answer is whether the presence of residual symptoms,
including psychotic and specifically negative symptoms, in
schizophrenia explains the poorer cognitive performance
in schizophrenia? We hypothesise that the difference in
cognitive performance could be explained by the presence of
residual symptoms.
2. Materials and Methods
The study received ethical approval from the institutional
ethics review board, and all subjects gave written informed
consent. Twenty-five 18–60 year-old subjects were recruited
into each group. Both the patient groups were recruited from
the outpatients’ clinics of BYL Nair Hospital. Those in the
bipolar disorder group (BD), fulfilled the DSM IV criteria
for bipolar I disorder—most recent episode manic—severe
without psychotic features (with no life-time history of a
psychotic episode confirmed using MINI 5.0). Those in the
schizophrenia group (SZ), fulfilled the DSM IV criteria for
schizophrenia [10, 11]. Euthymia was ascertained using a cut-
off score of less than 8 on Hamilton Depression Rating Scale
(HRSD) and Young Mania Rating Scale (YMRS) [12, 13].
Remission in schizophrenia was confirmed using a cut-off
score of 8 with a score of less than 2 on individual items
on the Brief Psychiatric Rating Scale (BPRS) and Scale for
the Assessment of Negative Symptoms (SANS) [9, 14, 15].
Antipsychotic doses were measured using the defined daily
dose (DDD) method described by WHO [16]. The control
group consisted of 25 healthy subjects who had no past
or family history of major psychiatric illness in a first-
degree relative. Subjects with comorbid Axis I (including
substance use disorder—except nicotine use based on MINI
5.0 screening) and Axis II diagnoses, those with medical
comorbidity, and those who had received ECT in the last 6
months were excluded.
2.1. Cognitive Assessment
2.1.1. Verbal and Visual Memory. Memory was assessed using
Postgraduate Institute Memory Scale (PGIMS), an Indian
adaptation of Wechsler memory scale and Boston memory
scale that takes into account the language, educational level,
and norms standardized for the Indian population [17].
Dysfunction scores adjusted for education level are scored
0, 2, or 3, with higher scores suggesting greater dysfunction.
We used the total dysfunction score as well as the raw scores
on digit span tests. The Rey-Osterrieth complex figure test
with copy component (ROCFT1) and a 30-minute recall
component (ROCFT2) was used to evaluate visual attention
(copy component), visuoconstructional ability, and delayed
visual memory [18].
2.1.2. Trail-Making Test (TMT). TMT A and B have been
commonly used and validated in the Indian population [19].
2.1.3. Verbal Fluency. Based on previous studies of verbal flu-
ency, one Hindi phoneme (denoted in English as /p/[“pa:”])
was used in this task and participants were asked to generate
words that started with the sounds associated with these
letters in the 60 s time limit. The total number of words in
the trial, after excluding proper nouns, numbers, andmultiple
forms of the same root word, was taken as the verbal fluency
score [20].
2.1.4. Go-No Go Task. Sensitivity to interference and
inhibitory control was tested using a two-step go-no go task,
as described in the frontal assessment battery [21]. In the first
task, the subject was asked to provide an opposite response
to the examiner’s alternating signal. Thus, the subject should
obey the initial verbal command and refrain following what
they see. On the second task, the subject must inhibit a
response that was previously given to the same stimulus. A
total of the correct responses on the two tests were taken as
the total score.
3. Statistical Analysis
Firstly, we examined zero-order correlation between demo-
graphic/clinical variables and cognition (b path on medi-
ation). To address our first aim, we compared cognitive
function between groups using MANCOVA, with cognitive
functions as dependent variable, diagnosis as the fixed factor,
and those variables that correlated with cognitive function
(dependent variable), but not diagnostic group (independent
variable), as covariates [22]. We correlated the effect sizes of
cognitive deficits between the two diagnostic groups to look
at the similarity of cognitive deficits, as previously done by
Schretlen et al. [3].
Finally, to address our second aim, we conducted a
mediation analysis to see if variables, SANS, BPRS, and DDD
(mediators), that differed significantly between diagnostic
groups mediated the relationship between group mem-
bership (independent variable: IV) and cognitive function
(dependent variable: DV) in each domain. The analysis tests
the hypothesis that the diagnostic category (IV) accounts for
variance in the mediator and in turn, this variance in the
mediator accounts for a proportion of the variance of the
cognitive deficits (DV) (Figure 1). “The adjustable param-
eters of the model represent the unidirectional influence
between pairs of variable in the model. The best fitting
values of the parameters are estimated by using the General
Linear Model to solve the linear equations that describe
the relationships within the model. This analysis differs
from multiple regression which estimates the proportion of
variance in the dependent variable accounted for by each of
several independent predictor variableswhile allowing for the
variance accounted for by the other predictors in the model.
In other words, themediation analysis partitions the variance
explained by the predictor into a part that is independent of
the mediating variable and a part that is accounted for via the
mediating variable” [23]. In classic mediation analysis, causal
models are tested using longitudinal data; such an assumption
was not made here. The purpose of this analysis was to
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Table 1: Demographic and illness characteristics.
BP SZ HC Test statistic 𝑃 BP versus SZ
Female, 𝑛 (%) 7 (28) 9 (36) 7 (28) Chi square = 0.502 0.778
Age, years :mean (s.d.) 35.44 (11.18) 40.16 (8.153) 35.48 (5.49) 𝐹 = 2.49b 0.09
Years in education 10.08 (2.08) 9.08 (1.47) 9.92 (1.03) 𝐹 = 2.86b 0.064
Unemployed 3 6 0 2.7𝐸 − 09a <0.001 NS
YMRS, mean (s.d.) 2.28 (1.1) 2.04 (1.02) 0 𝐹 = 52.32b <0.001 NS
HRSD, mean (s.d.) 1.52 (0.58) 1.36 (0.95) 0 𝐹 = 41.85b <0.001 NS
BPRS, mean (s.d.) 0.56 (0.65) 3.68 (1.24) 0 𝐹 = 148.67b <0.001 𝑡 = −11.07; 𝑃 < 0.001
SANS, mean (s.d.) 0.32 (0.55) 2.68 (0.69) 0 𝐹 = 204.2b <0.001 𝑡 = −13.3; 𝑃 < 0.001
IDEAS, mean (s.d.) 1.52 (2.00) 2.16 (2.26) — 𝐹 = 1.12b 0.295
Number of manic episodes, mean (s.d.) 2.88 (1.45) — —
Number of depressive episodes, mean (s.d.) 1.08 (1.57) — —
Duration of illness, mean (s.d.) 8.48 (6.61) 11.32 (5.81) — 𝐹 = 2.6b 0.113
Medication
DDD 0.72 (0.50) 1.68 (0.62) 𝑡 = −5.94; <0.001
Lithium, 𝑛 (%) 7 (28) — —
Valproate, 𝑛 (%) 6 (24) — —
Carbamazepine, 𝑛 (%) 6 (24) — —
Lithium + carbamazepine, 𝑛 (%) 6 (24) — —
Antipsychotics, 𝑛 (%) 18 (72) 25 (100) —
Benzodiazepine, 𝑛 (%) 5 (20) 8 (32) —
Anticholinergics, 𝑛 (%) 8 (32) 24 (96) —
Antidepressant, 𝑛 (%) 3 (12) 3 (12) —
aFisher’s exact test for rXc tables; bANOVA IDEAS: Indian Disability Evaluation and Assessment Scale; DDD: defined daily dose of antipsychotics; BP: bipolar
disorder; SZ: schizophrenia; HC: healthy control; BPRS: Brief Psychiatric Rating Scale (measured on a scale of 0–6 as in [9]); HDRS: Hamilton Depression
Rating Scale; YMRS: Young Mania Rating Scale; SANS: Scale for the Assessment of Negative Symptoms.
identify overlapping variance in cognitive function, explained
by the diagnostic groups and mediator variables. This type
of approach has been taken previously to examine the
contribution ofMRI surface basedmeasures to volume-based
measures measured using VBM [19]. We used the bootstrap
method of Preacher and Hayes to estimate the indirect effect
and bias-corrected 95% confidence interval (CI) for each
mediator based on 20,000 bootstrap samples using an SPSS
macro [24]. This analysis requires no assumption regarding
the underlying distributions since the statistical significance
level is determined nonparametrically.
4. Results
Demographic and illness variables are shown in Table 1. The
two patient groups did not differ on most of the variables.
Notably, BPRS, SANS scores, and defined daily dose (DDD)
of antipsychotics were greater in the schizophrenia group
compared to the bipolar group.
The results of the correlation are shown in Table 2.
Age showed a significant association with performance on
trail-making test. HDRS scores were associated with mem-
ory dysfunction. DDD of medication was associated with
poorer performance on digit forward trail-making test B and
ROCFT. There was also a significant association between
BPRS and SANS across a number of domains.
Diagnosis 
(independent)
Cognitive 
function 
(dependent)
SANS, 
BPRS, DDD 
(mediator)
Direct effect  
Total effect 
Indirect effect 
a b
Figure 1: Mediation analysis. The figure depicts the relationship
between the independent, mediator, and dependent variables.
The mediation analysis partitions the total variance (total effect)
explained by the predictor into a part that is independent of the
mediating variable (direct effect) and a part that is accounted for via
the mediating variable (indirect effect). a represents the “a” path and
b represents the “b” path.
Mean effect size of cognitive deficits was 𝜂2
𝑝
= −0.56 in
bipolar disorder and 𝜂2
𝑝
= −0.72 in schizophrenia. Figure 2
shows the relationship between the effect sizes of cognitive
function in both groups. As can be seen, patients performed
worse than controls on all tests, after controlling for gender,
age, and number of years in education. Performing a Pearson’s
correlation of effect sizes between groups tested the similarity
of cognitive deficits. This was found to be 𝑟 = 0.88.
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Table 2: Spearman’s correlation between clinical and demographic variables and performance on cognitive tests.
Digit
forward
Digit
backward
Trail making
A
Trail making
B
Verbal
fluency Go-no go ROCFT1 ROCFT2 PGIMS
Age −0.164 −0.032 −0.313∗ 0.263 −0.247 −0.183 0.075 −0.187 0.191
Number of years in
education 0.119 0.069 −0.045 −0.156 0.235 0.031 0.127 0.268 0.066
Duration of illness in
years −0.082 0.256 −0.079 0.096 −0.122 −0.132 0.123 −0.215 0.047
DDD −0.362∗∗ −0.186 0.146 0.433∗∗ −0.245 −0.160 −0.016 −0.500∗∗ 0.483∗∗
YMRS 0.137 0.191 −0.175 −0.151 0.154 0.169 −0.052 0.040 −0.056
HDRS 0.213 −0.010 0.244 −0.126 −0.186 −0.154 0.094 0.170 −0.300∗
BPRS −0.617∗∗ −0.282∗ 0.172 0.575∗∗ −0.478∗∗ −0.298∗ 0.097 −0.589∗∗ 0.558∗∗
SANS −0.526∗∗ −0.239 0.157 0.466∗∗ −0.488∗∗ −0.511∗∗ 0.120 −0.530∗∗ 0.526∗∗
Total IDEAS −0.374∗∗ −0.416∗∗ −0.048 0.131 −0.119 −0.331∗ 0.054 −0.117 0.434∗∗
∗
𝑃 < 0.05; ∗∗𝑃 < 0.01; DDD: defined daily dose of antipsychotics; BPRS: Brief Psychiatric Rating Scale; HDRS: Hamilton Depression Rating Scale; YMRS:
Young Mania Rating Scale; SANS: Scale for the Assessment of Negative Symptoms; IDEAS: Indian Disability Evaluation and Assessment Scale.
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Figure 2: Comparison of effect sizes of differences between cases and controls. Partial eta squared represents the size of the relationship
between diagnosis and cognitive function. Greater values represent greater cognitive deficits. Covariates appearing in themodel are evaluated
at the following values: gender = 0.3067, number of years in education = 9.69, and age = 37.03. FDS: forward digit span; RDS: reverse digit
span; TMT A: trail-making test A; TMT B: trail-making test B; ROCFT-ROCFT: Rey Osterreith Complex figure test; PGIMS: PGI memory
scale.
Results of MANCOVA comparing the patient groups
are shown in Table 3. Diagnosis was significantly associated
with cognitive performance [Pillai’s trace = 0.73; 𝐹(9, 35) =
10.41; 𝑃 < 0.001; 𝜂2
𝑝
= 0.73]. SANS, BPRS, and DDD
were not included as covariates in the above model, as they
differed significantly between the patient groups. They were
considered as potential mediators.
Onmediation analysis, we found that SANSmediated the
difference in performance between the two groups on trail-
makingB (Beta =−30.46;𝑍 = −3.07; 95%CI=−49.67–−6.52),
verbal fluency (Beta = −2.24; 𝑍 = −2.65; 95%CI = −4.16–
−0.18), go-no go test (Beta = −1.59; 𝑍 = −3.97; 95%CI =
−2.615–−0.61), and ROCFT2 (Beta = 2.45;𝑍 = 2.09; 95%CI =
0.17–4.89). BPRS and DDD showed no mediation effects.
5. Discussion
Wehave shown that clinically stable patientswith schizophre-
nia and bipolar disorder have qualitatively similar cognitive
deficits. These deficits are quantitatively greater in patients
with schizophrenia. This difference in performance between
the patients groups was at least in part mediated by residual
negative symptoms.
Recent review of meta-analyses of cognitive function in
patients with remitted bipolar disorder and schizophrenia
showed a weighted effect size in the range of 0.6 and 0.8–1 for
letter fluency; 0.7 and 0.9 on trail-making tests; 0.7 and 0.9
on digit span backwards; 0.8 and 1.3 on verbal learning and
recall, respectively [1]. Findings of our study confirm the large
effect sizes observed by the aforementioned investigators
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Table 3: Comparison of cognitive performance between patient
groups.
Bipolara Schizophreniaa 𝐹 Sig
Total PGIMS 11.26a 17.94a 33.735 <0.001
Digit span forward 4.75a 3.57a 26.771 <0.001
Digit span backward 2.84a 2.32a 5.011 0.030
ROCFT 1 31.57a 31.71a 0.094 0.761
ROCFT 2 18.44a 14.55a 31.243 <0.001
Trail-making A 70.81a 78.99a 1.761 0.192
Trail-making B 118.99a 149.37a 24.107 <0.001
Verbal fluency test 13.06a 11.82a 5.371 0.025
Go-no go test 5.52a 4.84a 6.694 0.013
aEstimated marginal means; covariates appearing in the model are evaluated
at the following values: age = 37.80, gender = 0.3200, number of years
in education = 9.58, hdrs = 1.44, ymrs = 2.16. Adjustment for multiple
comparisons: Bonferroni. ROCFT: Rey Osterreith Complex figure test;
PGIMS: PGI memory scale.
in a sample from a developing country. The effect sizes
of cognitive deficits in bipolar disorder and schizophrenia
showed a high degree of correlation, suggesting deficits in
qualitatively similar cognitive function. Schretlen et al. pre-
viously compared cognitive functioning in bipolar disorder
(𝑑 = −0.59) with schizophrenia (𝑑 = −0.97) [3]. They found
good correlation (𝑟 = 0.71) of effect sizes of cognitive tests
between the two illnesses, a finding replicated in our study
(𝑟 = 0.88). Similar results have also been shown by studies
by Siedman et al. (𝑟 = 0.81) and Dickerson et al. (𝑟 = 0.93)
[25, 26].
Most interestingly, using mediation analysis, we found
that residual negative symptoms mediated the relationship
between diagnosis and cognitive function, particularly on the
executive function domain. This implies that negative symp-
toms and cognitive symptoms share significant common
variance. In other words, poorer performance on cognitive
tests by patients with schizophrenia is, at least in part,
explained by the presence of residual negative symptoms in
patients with schizophrenia. Neither residual BPRS scores
nor greater DDD explained this relationship. This finding
is in contrast to those of Simonsen et al., who found that
neurocognitive dysfunction was more strongly determined
by a history of psychosis [5].
Data from longitudinal studies examining the relation-
ship between negative symptoms and cognitive dysfunc-
tion have demonstrated a temporal link between the two.
Nevertheless, cognitive and negative symptoms have been
shown to be sufficiently independent of each other, imply-
ing differential involvement of brain regions in these two
processes [7]. More recently, Farzan et al. examined cortical
inhibition of gamma band oscillations (CI
𝛾
) in patients
with schizophrenia and bipolar disorder. They found that
patients with schizophrenia demonstrated selective deficits
in CI
𝛾
in the DLPFC compared to bipolar disorder and
healthy subjects. They suggest that this lack of inhibition
of gamma oscillations in the dorsolateral prefrontal cor-
tex may represent a frontal neurophysiological deficit that
could be responsible for the spectrum of frontal deficits
in patients with schizophrenia, including executive and
cognitive control deficits and negative symptoms [27, 28].
While we cannot make conclusions about the pathophys-
iology of these illnesses, our findings may be explained
by the greater deficits in these physiological processes in
patients with schizophrenia, compared to those with bipolar
disorder.
While the positive aspect of our study includes the use
of standardised tests in a clinical sample free of substance
use and other comorbidities, the study has a number of
limitations. The small sample size might have led to a type-
2 error. However, the observation that negative symptoms
(SANS)mediated the difference in cognitive function, despite
the small sample size, suggests that the relationship is robust.
It should also be noted that the bias-corrected bootstrapping
method for testing the mediation is relatively robust against
the effect of small sample sizes, especially when the effect sizes
of the “a” path and “b” path of the mediation are large as
in our sample. A possible explanation for the finding in our
study is that SANS designates a number of occupational and
educational performance deficits as negative symptoms that
are linkedwith poor cognitive function [7]. It could be argued
that BPRS is a general measure of psychopathology, rather
than just a measure of psychosis. However, in our sample,
we found that BPRS scores did not correlate significantly
with any of the other psychopathology scores in patients
with schizophrenia. We did not test the premorbid IQ of the
patients. Previous studies have indeed shown that the differ-
ence in premorbid IQ could explain some of the differences in
performance on verbal fluency and response inhibition tests
[29]. Premorbid IQ has also been shown previously to link
to negative symptoms. However, previous validating studies
have shown that scores on PGIMS show low correlation
with IQ [17]. The present study did not confirm remission
prospectively. While we excluded those with a history of
substance use disorder or recent substance use, this exclusion
was based on self-report (and MINI screen). We did not
use laboratory methods to rule out recent substance use
that may have influenced performance on the cognitive tests.
Finally, it is not known how generalizable the data is to the
community, where symptoms might not be as controlled as
in the population tested.
6. Conclusions
Persistent cognitive deficits are seen in patientswith euthymic
bipolar disorder and schizophrenia under remission when
compared to healthy controls. The cognitive deficits are
qualitatively similar but worse in patients with schizophrenia
compared to patients with bipolar disorder. The worse cog-
nitive function in patients with schizophrenia was mediated
by the presence of residual negative symptoms. Further work
exploring the link between negative symptoms, cognitive
symptoms, and neurophysiological measures may provide
insight into pathophysiological mechanisms that may under-
lie these deficits.
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